A new analysis has found that Australia’s medical research institutes are not only advancing science but also delivering substantial economic value and strengthening the nation’s healthcare capability.
The report, released by the Association of Australian Medical Research Institutes and prepared by Nous Group, paints a clear picture of a sector that is both economically productive and vital to national wellbeing.
According to the findings, Australia’s medical research institutes generate an estimated $4.07 billion in annual economic benefits, returning $3.90 for every dollar invested. Clinical trials stand out as an even stronger contributor, delivering a return of 5.80 dollars per dollar invested while giving patients early access to potentially life-saving treatments.
National frameworks such as Ambitious Australia and the National Health and Medical Research Strategy have already highlighted the importance of research and development in driving productivity, economic growth and improved health outcomes. The new analysis reinforces the message that sustained and strategic investment in medical research is essential to securing long-term national prosperity.
The report emphasises the central role medical research institutes play within Australia’s broader health and innovation ecosystem. These institutes work closely with hospitals, universities and industry partners, enabling clinical trials, translating discoveries into real-world treatments and supporting the development of new therapies and technologies.
Jason Kovacic, President of AAMRI, described the institutes as a critical national asset that bridges scientific discovery and patient care. He explained that their unique model brings together clinicians, scientists, and patients to ensure research moves efficiently into clinical practice, ultimately improving patient outcomes while supporting collaboration and long-term economic growth.
The report also highlights the sector’s role in creating highly skilled jobs, advancing biotechnology and medical technology industries and strengthening Australia’s position in global research. Saraid Billiards, Chief Executive of AAMRI, noted that the independence of these institutes, combined with their strong links to hospitals and focus on translation, allows them to deliver research that has immediate and meaningful impact on patient care.
However, the analysis also points to growing pressure on the funding model that supports these institutions. While government funding typically covers direct research costs, the significant indirect costs associated with infrastructure, equipment, data systems and specialist staff are only partially funded. As a result, institutes are increasingly relying on philanthropy, commercial activities and internal reserves to fill the gap.
Without reform, the report warns that many institutes could face serious financial sustainability challenges in the coming decade. This would place Australia’s research capacity and the future health and economic benefits it delivers at risk.
Dr Billiards stressed that aligning funding with the true cost of research is essential to maintaining the sector’s strength. A sustainable model, she said, would ensure institutes can continue delivering the outcomes relied upon by government, patients and the broader community, including clinical trials, research translation and workforce development.
The report recommends targeted reforms, particularly increasing funding to better reflect the actual costs of conducting research. Professor Kovacic concluded that, with the right policy settings in place, Australia’s medical research institutes will remain one of the nation’s highest-return investments, continuing to deliver breakthroughs that improve lives and strengthen the healthcare system.